Money

Found 79,340 articles

• Solarea Bio Announces First Close of Series B Financing Round

  5/8/2023

  Solarea Bio announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF.

• SomaLogic opens their first-ever proteomics grant program to APAC life sciences researchers

  5/8/2023

  SomaLogic, Inc., a global leader in proteomics technology, announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore.

• BioNTech Announces First Quarter 2023 Financial Results and Corporate Update

  5/8/2023

  BioNTech SE reported financial results for the three months ended March 31, 2023, and provided an update on its corporate progress.

• BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023

  5/8/2023

  BiomX Inc. announced that the Company will host a conference call and a live audio webcast on Monday, May 15th, 2023, at 8:00 a.m. ET, to report first quarter 2023 financial results and provide business updates.

• Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

  5/8/2023

  Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that the Company will release its first quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, May 11, 2023.

• ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

  5/8/2023

  ANI Pharmaceuticals, Inc. announced business highlights and financial results for the three months ended March 31, 2023.

• Almirall’s First Quarter 2023 Results

  5/8/2023

  Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its Q1 2023 financial results.

• Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update

  5/8/2023

  Pharvaris reported financial results for the first quarter ended March 31, 2023 and provided a business update.

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 05, 2023

  5/5/2023

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 18 new employees.

• VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update

  5/5/2023

  VolitionRx Limited announced it will host a conference call on Thursday May 11 at 08.30 a.m. Eastern Time to discuss its financial and operating results for the first quarter 2023, in addition to providing a business update.

• Heska Corporation Reports First Quarter 2023 Results

  5/5/2023

  Heska Corporation, a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results for its first quarter ended March 31, 2023.

• Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

  5/5/2023

  Trinity Biotech plc reported the receipt of a formal notification from The Nasdaq Stock Market LLC that the Company has regained compliance with Listing Rule 5450, which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.

• Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

  5/5/2023

  Impel Pharmaceuticals Inc. announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.

• Assertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11:30 am Eastern Time

  5/5/2023

  Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, before the market open.

• Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023

  5/5/2023

  Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2023, on Friday, May 12, 2023.

• Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

  5/5/2023

  Amylyx Pharmaceuticals, Inc. will report its first quarter 2023 financial results on Thursday, May 11, 2023, following the close of the U.S. financial markets.

• InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update

  5/5/2023

  InspireMD, Inc. announced it will now report first quarter 2023 financial results on Monday, May 15th, 2023.

• Soligenix Announces Pricing of $8.5 Million Public Offering

  5/5/2023

  Soligenix, Inc. announced the pricing of its public offering of 6,538,500 shares of common stock and warrants to purchase up to 6,538,500 shares of common stock at a combined public offering price of $1.30 per share and accompanying warrant for aggregate gross proceeds of approximately $8.5 million, before deducting placement agent fees and other offering expenses.

• Co-Diagnostics, Inc. Announces First Quarter 2023 Earnings Release Date and Webcast

  5/5/2023

  Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced it will release its first quarter 2023 results on Thursday, May 11, 2023, after the market close.

• Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  5/5/2023

  Morphic Holding, Inc. announced the closing of an underwritten public offering of 6,133,334 shares of its common stock at a price to the public of $45.00 per share, which includes 800,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock.